Evidence map›Paper›PMID 33775123›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2021

Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Kaisa M Mäki-Petäjä, Adam McGeoch, Lucy L Yang, Annette Hubsch, Carmel M McEniery, Paul A R Meyer, Fraz Mir, Parag Gajendragadkar, Nicola Ramenatte, Gayathri Anandappa and 8 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Kaisa M Mäki-Petäjä *Division of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Adam McGeoch *Division of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Lucy L YangDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Annette HubschDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Carmel M McEnieryDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Paul A R MeyerDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Fraz MirDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Parag GajendragadkarDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Nicola RamenatteCambridge Clinical Trials Unit (N.R., S.J.B., I.B.W., D.I.J., J.C.), Cambridge University Hospitals NHS Foundation Trust, United Kingdom.
Gayathri AnandappaDepartment of Oncology (G.A., D.I.J.), University of Cambridge, United Kingdom.
Sara Santos FrancoGlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, United Kingdom (S.S.F.).
Simon J BondCambridge Clinical Trials Unit (N.R., S.J.B., I.B.W., D.I.J., J.C.), Cambridge University Hospitals NHS Foundation Trust, United Kingdom.
Carola-Bibiane SchönliebDepartment of Applied Mathematics and Theoretical Physics (C.-B.S.), University of Cambridge, United Kingdom.
Yoeri BoinkDepartment of Applied Mathematics (Y.B., C.B.), University of Twente, the Netherlands.
Christoph BruneDepartment of Applied Mathematics (Y.B., C.B.), University of Twente, the Netherlands.
Ian B WilkinsonDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
Duncan I JodrellDepartment of Oncology (G.A., D.I.J.), University of Cambridge, United Kingdom.
Joseph CheriyanDivision of Experimental Medicine and Immunotherapeutics (K.M.M.-P., A.M., L.L.Y., A.H., C.M.M., P.A.R.M., F.M., P.G., I.B.W., J.C.), University of Cambridge, United Kingdom.
MACOM (United States) · USUniversity of Cambridge · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity of Twente · NLGlaxoSmithKline (United Kingdom) · GB

Funding

Cancer Research UK 15678Wellcome Trust 100780
6 · The paper itself

Abstract

[Figure: see text].

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsCardiac OutputEndothelium, VascularFemaleHemodynamicsHumansHypertensionIndazolesMaleMiddle AgedNeoplasmsPyrimidinesReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsIndazolespazopanibPyrimidinesReceptors, Vascular Endothelial Growth FactorSulfonamidesacetylcholinecardiovascular diseasehypertensionmicrovascular rarefactionpazopanib

Identifiers

PMID33775123
PMCPMC7610566
OpenAlexW3150651718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.